S&P 500   3,972.35 (-2.85%)
DOW   31,867.80 (-2.41%)
QQQ   296.14 (-3.28%)
AAPL   143.54 (-3.82%)
MSFT   257.25 (-3.59%)
FB   196.07 (-3.23%)
GOOGL   2,263.13 (-2.85%)
AMZN   2,183.86 (-5.35%)
TSLA   731.31 (-3.98%)
NVDA   173.93 (-4.31%)
BABA   89.37 (-2.85%)
NIO   16.25 (-2.29%)
AMD   98.77 (-3.61%)
CGC   5.77 (-2.04%)
MU   72.02 (-3.30%)
T   20.46 (-0.53%)
GE   75.65 (-0.98%)
F   13.02 (-3.77%)
DIS   105.81 (-2.60%)
AMC   13.47 (+4.42%)
PFE   50.58 (-1.48%)
PYPL   78.10 (-2.07%)
NFLX   182.77 (-4.09%)
S&P 500   3,972.35 (-2.85%)
DOW   31,867.80 (-2.41%)
QQQ   296.14 (-3.28%)
AAPL   143.54 (-3.82%)
MSFT   257.25 (-3.59%)
FB   196.07 (-3.23%)
GOOGL   2,263.13 (-2.85%)
AMZN   2,183.86 (-5.35%)
TSLA   731.31 (-3.98%)
NVDA   173.93 (-4.31%)
BABA   89.37 (-2.85%)
NIO   16.25 (-2.29%)
AMD   98.77 (-3.61%)
CGC   5.77 (-2.04%)
MU   72.02 (-3.30%)
T   20.46 (-0.53%)
GE   75.65 (-0.98%)
F   13.02 (-3.77%)
DIS   105.81 (-2.60%)
AMC   13.47 (+4.42%)
PFE   50.58 (-1.48%)
PYPL   78.10 (-2.07%)
NFLX   182.77 (-4.09%)
S&P 500   3,972.35 (-2.85%)
DOW   31,867.80 (-2.41%)
QQQ   296.14 (-3.28%)
AAPL   143.54 (-3.82%)
MSFT   257.25 (-3.59%)
FB   196.07 (-3.23%)
GOOGL   2,263.13 (-2.85%)
AMZN   2,183.86 (-5.35%)
TSLA   731.31 (-3.98%)
NVDA   173.93 (-4.31%)
BABA   89.37 (-2.85%)
NIO   16.25 (-2.29%)
AMD   98.77 (-3.61%)
CGC   5.77 (-2.04%)
MU   72.02 (-3.30%)
T   20.46 (-0.53%)
GE   75.65 (-0.98%)
F   13.02 (-3.77%)
DIS   105.81 (-2.60%)
AMC   13.47 (+4.42%)
PFE   50.58 (-1.48%)
PYPL   78.10 (-2.07%)
NFLX   182.77 (-4.09%)
S&P 500   3,972.35 (-2.85%)
DOW   31,867.80 (-2.41%)
QQQ   296.14 (-3.28%)
AAPL   143.54 (-3.82%)
MSFT   257.25 (-3.59%)
FB   196.07 (-3.23%)
GOOGL   2,263.13 (-2.85%)
AMZN   2,183.86 (-5.35%)
TSLA   731.31 (-3.98%)
NVDA   173.93 (-4.31%)
BABA   89.37 (-2.85%)
NIO   16.25 (-2.29%)
AMD   98.77 (-3.61%)
CGC   5.77 (-2.04%)
MU   72.02 (-3.30%)
T   20.46 (-0.53%)
GE   75.65 (-0.98%)
F   13.02 (-3.77%)
DIS   105.81 (-2.60%)
AMC   13.47 (+4.42%)
PFE   50.58 (-1.48%)
PYPL   78.10 (-2.07%)
NFLX   182.77 (-4.09%)
NASDAQ:SPNE

SeaSpine (SPNE) Stock Forecast, Price & News

$8.40
-0.03 (-0.36%)
(As of 05/18/2022 11:38 AM ET)
Add
Compare
Today's Range
$8.25
$8.44
50-Day Range
$8.05
$12.71
52-Week Range
$8.00
$22.00
Volume
243 shs
Average Volume
108,680 shs
Market Capitalization
$309.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.28
30 days | 90 days | 365 days | Advanced Chart
Receive SPNE News and Ratings via Email

Sign-up to receive the latest news and ratings for SeaSpine and its competitors with MarketBeat's FREE daily newsletter.

SeaSpine logo

About SeaSpine

SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. The company's orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. It also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. In addition, the company offers implant products for spinal decompression, alignment, stabilization, and image-guided surgical solutions, as well as a surgical navigation system used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SPNE
Fax
N/A
Employees
523
Year Founded
N/A

Sales & Book Value

Annual Sales
$191.45 million
Book Value
$8.57 per share

Profitability

Net Income
$-54.35 million
Pretax Margin
-29.76%

Debt

Price-To-Earnings

Miscellaneous

Free Float
32,896,000
Market Cap
$309.12 million
Optionable
Optionable

Company Calendar

Last Earnings
5/03/2022
Today
5/18/2022
Next Earnings (Estimated)
8/01/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.52 out of 5 stars

Medical Sector

123rd out of 1,426 stocks

Surgical & Medical Instruments Industry

15th out of 138 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -













SeaSpine (NASDAQ:SPNE) Frequently Asked Questions

Is SeaSpine a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SeaSpine in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SeaSpine stock.
View analyst ratings for SeaSpine
or view top-rated stocks.

Are investors shorting SeaSpine?

SeaSpine saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 536,500 shares, a drop of 23.4% from the April 15th total of 700,500 shares. Based on an average daily volume of 91,300 shares, the days-to-cover ratio is currently 5.9 days. Approximately 1.7% of the company's shares are sold short.
View SeaSpine's Short Interest
.

When is SeaSpine's next earnings date?

SeaSpine is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022.
View our earnings forecast for SeaSpine
.

How were SeaSpine's earnings last quarter?

SeaSpine Holdings Co. (NASDAQ:SPNE) released its quarterly earnings results on Tuesday, May, 3rd. The medical equipment provider reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.09. The medical equipment provider had revenue of $50.69 million for the quarter, compared to analysts' expectations of $48.96 million. SeaSpine had a negative net margin of 29.09% and a negative trailing twelve-month return on equity of 20.19%. SeaSpine's revenue for the quarter was up 20.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.46) EPS.
View SeaSpine's earnings history
.

What guidance has SeaSpine issued on next quarter's earnings?

SeaSpine updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $231.00 million-$235.00 million, compared to the consensus revenue estimate of $228.44 million.

What price target have analysts set for SPNE?

6 analysts have issued 12-month price targets for SeaSpine's shares. Their forecasts range from $16.00 to $100.00. On average, they expect SeaSpine's share price to reach $33.50 in the next year. This suggests a possible upside of 298.8% from the stock's current price.
View analysts' price targets for SeaSpine
or view top-rated stocks among Wall Street analysts.

Who are SeaSpine's key executives?
SeaSpine's management team includes the following people:
  • Mr. Keith C. Valentine, Pres, CEO & Director (Age 54, Pay $977.29k)
  • Mr. John J. Bostjancic, Sr. VP, CFO & Treasurer (Age 51, Pay $556.62k)
  • Dr. Beau Standish P.Eng., Ph.D., Pres of Enabling Technologies (Age 42, Pay $345.15k)
  • Dr. Frank Vizesi, Chief Scientific Officer
  • Carrie Mendivil, Head of Investor Relations
  • Mr. Patrick L. Keran J.D., Sr. VP, Gen. Counsel & Sec. (Age 50)
  • Mr. John J. Winge, VP of Sales (Age 55)
  • Mr. Tyler P. Lipschultz, Sr. VP of Orthobiologics & Bus. Devel. (Age 55)
  • Mr. Dennis L. Cirino, Sr. VP of Global Spinal Systems (Age 52)
  • Paul Benny, VP, Corp. Controller, Assistant Treasurer & Assistant Sec.
What is Keith Valentine's approval rating as SeaSpine's CEO?

23 employees have rated SeaSpine CEO Keith Valentine on Glassdoor.com. Keith Valentine has an approval rating of 79% among SeaSpine's employees.

What other stocks do shareholders of SeaSpine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SeaSpine investors own include AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD), Kura Oncology (KURA), Recro Pharma (REPH), Rigel Pharmaceuticals (RIGL), Spectrum Pharmaceuticals (SPPI), ViewRay (VRAY), Verastem (VSTM) and Akorn (AKRX).

What is SeaSpine's stock symbol?

SeaSpine trades on the NASDAQ under the ticker symbol "SPNE."

Who are SeaSpine's major shareholders?

SeaSpine's stock is owned by a number of retail and institutional investors. Top institutional shareholders include First Light Asset Management LLC (19.04%), BlackRock Inc. (6.64%), Emerald Advisers LLC (2.51%), Dimensional Fund Advisors LP (2.11%), Emerald Mutual Fund Advisers Trust (2.04%) and State Street Corp (1.87%). Company insiders that own SeaSpine stock include Beau Standish, John B Henneman III and Renee Gaeta.
View institutional ownership trends for SeaSpine
.

Which major investors are selling SeaSpine stock?

SPNE stock was sold by a variety of institutional investors in the last quarter, including Polar Asset Management Partners Inc., BlackRock Inc., State Street Corp, Emerald Mutual Fund Advisers Trust, Northern Trust Corp, Renaissance Technologies LLC, GW&K Investment Management LLC, and Mutual of America Capital Management LLC. Company insiders that have sold SeaSpine company stock in the last year include Beau Standish, and Renee Gaeta.
View insider buying and selling activity for SeaSpine
or view top insider-selling stocks.

Which major investors are buying SeaSpine stock?

SPNE stock was purchased by a variety of institutional investors in the last quarter, including CI Investments Inc., First Light Asset Management LLC, Emerald Advisers LLC, Dimensional Fund Advisors LP, Assenagon Asset Management S.A., First Eagle Investment Management LLC, Raymond James & Associates, and Next Century Growth Investors LLC.
View insider buying and selling activity for SeaSpine
or or view top insider-buying stocks.

How do I buy shares of SeaSpine?

Shares of SPNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SeaSpine's stock price today?

One share of SPNE stock can currently be purchased for approximately $8.40.

How much money does SeaSpine make?

SeaSpine has a market capitalization of $309.12 million and generates $191.45 million in revenue each year. The medical equipment provider earns $-54.35 million in net income (profit) each year or ($1.61) on an earnings per share basis.

How many employees does SeaSpine have?

SeaSpine employs 523 workers across the globe.

What is SeaSpine's official website?

The official website for SeaSpine is www.seaspine.com.

How can I contact SeaSpine?

SeaSpine's mailing address is 5770 ARMADA DRIVE, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at (760) 727-8399 or via email at [email protected].

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.